PL415332A1 - Composition of a dietary medium - Google Patents

Composition of a dietary medium

Info

Publication number
PL415332A1
PL415332A1 PL415332A PL41533215A PL415332A1 PL 415332 A1 PL415332 A1 PL 415332A1 PL 415332 A PL415332 A PL 415332A PL 41533215 A PL41533215 A PL 41533215A PL 415332 A1 PL415332 A1 PL 415332A1
Authority
PL
Poland
Prior art keywords
composition
extract
herb
urinary tract
application
Prior art date
Application number
PL415332A
Other languages
Polish (pl)
Other versions
PL233159B1 (en
Inventor
Zbigniew Majka
Sylwia Berdzik-Kalarus
Original Assignee
Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Spółka Z Ograniczoną Odpowiedzialnością filed Critical Adamed Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL415332A priority Critical patent/PL233159B1/en
Publication of PL415332A1 publication Critical patent/PL415332A1/en
Publication of PL233159B1 publication Critical patent/PL233159B1/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Zgłoszenie dotyczy kompozycji środka dietetycznego, zawierającej wyciąg z ziela liściokwiatu, wyciąg z ziela nawłoci, wyciąg pokrzywy zwyczajnej, wyciąg z ziela szałwii lekarskiej, chlorowodorek pirydoksyny oraz co najmniej jedną sól kwasu cytrynowego. Kompozycja może być stosowana do rozpuszczania kamieni nerkowych w drogach moczowych i/lub zapobiegania tworzenia kamieni nerkowych w drogach moczowych. Zgłoszenie obejmuje też jednostkę dawkowania zawierającą tę kompozycję.The application relates to a dietetic composition containing an extract of herb flower, goldenrod herb extract, nettle extract, sage herb extract, pyridoxine hydrochloride and at least one citric acid salt. The composition can be used to dissolve kidney stones in the urinary tract and / or to prevent kidney stone formation in the urinary tract. The application also includes a dosage unit containing this composition.

PL415332A 2015-12-15 2015-12-15 Composition of a dietary medium PL233159B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL415332A PL233159B1 (en) 2015-12-15 2015-12-15 Composition of a dietary medium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL415332A PL233159B1 (en) 2015-12-15 2015-12-15 Composition of a dietary medium

Publications (2)

Publication Number Publication Date
PL415332A1 true PL415332A1 (en) 2017-06-19
PL233159B1 PL233159B1 (en) 2019-09-30

Family

ID=59061538

Family Applications (1)

Application Number Title Priority Date Filing Date
PL415332A PL233159B1 (en) 2015-12-15 2015-12-15 Composition of a dietary medium

Country Status (1)

Country Link
PL (1) PL233159B1 (en)

Also Published As

Publication number Publication date
PL233159B1 (en) 2019-09-30

Similar Documents

Publication Publication Date Title
PH12018501226A1 (en) Methods for treating huntingtons disease
PH12015502792A1 (en) Crystalline bromodomain inhibitors
IL261884B (en) Compositions of natural extracts and use thereof in methods for preventing or treating diseases
IL255203B (en) Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201791516A1 (en) METHODS OF COMBINED TREATMENT OF MALIGNANT TUMORS
MX2015009105A (en) Solid solution compositions and use in chronic inflammation.
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
EA201691242A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZD9291
MY192532A (en) Liquid pharmaceutical composition
MX366317B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
EA201892287A1 (en) PHARMACEUTICAL COMBINATIONS FOR CANCER TREATMENT
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JO3326B1 (en) Tripeptide Epoxy Ketone Protease Inhibitors
MX2017003121A (en) Antibody formulations.
MD20160007A2 (en) Heterobicycloaryl RORC2 inhibitors and methods of use thereof
WO2016140933A3 (en) Immediate release soluble ibuprofen compositions
RS53457B (en) A composition and use thereof in the treatment of anal rhagades
MX2017013049A (en) Pharmaceutical salt forms of an inhibitor of semicarbazide-sensit ive amine oxidase (ssao).
WO2014130313A3 (en) Methods and compositions relating to the treatment of cancer
DK3334760T3 (en) Coated and uncoated antibody cysteines, and their use in antibody-drug conjugation
EA201992382A2 (en) ORAL TABLET PHARMACEUTICAL COMPOSITION FOR DOUBLE USE ON THE BASIS OF SULPHATE SALTS AND METHODS OF ITS APPLICATION
BR112017022534A2 (en) ? friction reduction terpolymer and its composition, reduction method and synthesis method?
EA201892842A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING SAFINAMID